OR
ORGS.US Orgenesis Inc
- Market cap
- USD 3.67M
- P/E
- -
- P/B
- 1.26x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is ORGS.US undervalued?
Graham numberThe Graham number of Orgenesis Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orgenesis Inc fundamental analysis
No fundamental analysis for Orgenesis Inc yet.
Orgenesis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include a…
Full company profileOrgenesis Inc financial statements
Orgenesis Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.97M | 6.40M | 10.1M | 18.7M | 33.3M | 7.65M | 35.5M | 36.0M | 530K | 1.04M |
| Gross Profit | -906K | -1.26M | 3.28M | 7.96M | 15.1M | -23.4M | 7.34M | 15.6M | -5.73M | -8.47M |
| Operating Income | -7.21M | 11.3M | -11.2M | -14.7M | -24.6M | -95.8M | -16.8M | -7.54M | -53.6M | -26.1M |
| EBITDA | -2.64M | -9.04M | -9.85M | -12.4M | -18.9M | -94.2M | -15.7M | -8.16M | -60.7M | -43.1M |
| Net Income | -4.46M | -9.19M | -12.4M | -18.3M | -26.0M | -95.8M | -18.1M | -14.9M | -55.4M | -48.2M |
| EPS | -0.94 | -1.08 | -1.27 | -1.37 | -1.64 | -4.49 | -0.74 | -0.59 | -1.91 | -9.31 |
| Balance Sheet | ||||||||||
| Total Assets | 38.7M | 33.5M | 39.9M | 75.4M | 92.5M | 77.7M | 59.8M | 90.9M | 14.6M | 1.35M |
| Total Liabilities | 45.2M | 22.9M | 25.7M | 46.8M | 86.4M | 25.0M | 21.2M | 31.7M | 35.5M | 38.9M |
| Shareholders' Equity | -6.44M | 10.6M | 14.1M | 28.4M | 5.48M | 52.6M | 38.5M | 27.6M | -21.0M | -37.5M |
| Cash & Short-term Investments | 4.17M | 891K | 3.52M | 16.1M | 11.4M | 44.9M | 5.47M | 5.31M | 837K | 78.0K |
| Total Debt | 10.3M | 9.84M | 7.69M | 3.73M | 24.8M | 12.9M | 11.8M | 20.3M | 22.6M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.71M | -3.78M | -3.83M | -15.7M | -13.2M | -78.0M | -26.9M | -24.9M | -14.8M | -17.1M |
| Capital Expenditure | 982K | 1.43M | 975K | 5.56M | 12.1M | 1.53M | 7.87M | 12.4M | 2.10M | 263K |
| Free Cash Flow | -3.69M | -5.21M | -4.81M | -21.2M | -25.3M | -79.6M | -34.7M | -37.3M | -16.9M | -17.3M |
| Ratios | ||||||||||
| ROE | - | -86.9% | -87.6% | -64.5% | -475.5% | -182.2% | -46.9% | -54.0% | - | - |
| ROA | -11.5% | -27.5% | -31.0% | -24.2% | -28.2% | -123.3% | -30.2% | -16.4% | -380.4% | -3,565.1% |
| Net Profit Margin | -150.0% | -143.7% | -122.6% | -98.0% | -78.3% | -1,252.1% | -50.9% | -41.3% | -10,445.5% | -4,653.6% |
| Debt to Equity | - | 0.93x | 0.54x | 0.13x | 4.52x | 0.25x | 0.31x | 0.74x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Orgenesis Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 106K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Sep 25, 2024.
Who owns Orgenesis Inc
- Insiders 46.42%
- Institutions 0.52%
- Public & others 53.06%
- Shares outstanding 9.80M
- Free float 3.64M
Top funds holding ORGS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 567K | 1.19% | 0.00% | Aug 2024 |
| Vanguard Institutional Extnd Mkt Idx Tr | 301K | 0.63% | 0.00% | Aug 2024 |
| Fidelity Extended Market Index | 176K | 0.37% | -1.58% | Aug 2024 |
| Fidelity Total Market Index | 40.8K | 0.09% | 0.00% | Aug 2024 |
| Vanguard Balanced Index Inv | 32.3K | 0.07% | 0.00% | Aug 2024 |
| Fidelity Series Total Market Index | 28.4K | 0.06% | 0.00% | Aug 2024 |
| SSgA U.S. Extended Market Index Class I | 21.0K | 0.04% | 0.00% | Dec 2023 |
| Northern Trust Extended Eq Market Idx | 20.5K | 0.04% | 0.00% | Jun 2024 |
| Spartan Total Market Index Pool E | 15.8K | 0.03% | +66.64% | Aug 2024 |
| Fidelity Nasdaq Composite Index | 14.9K | 0.03% | 0.00% | Aug 2024 |
| Vanguard Instl Ttl Stck Mkt Idx Tr | 14.9K | 0.03% | 0.00% | Mar 2024 |
| Spartan Extended Market Index Pool E | 13.5K | 0.03% | +26.58% | Aug 2024 |
| BlackRock Extended Equity Market K | 5.20K | 0.11% | -0.06% | Sep 2024 |
| NT Ext Equity Mkt Idx Fd - L | 2.05K | 0.04% | 0.00% | Sep 2024 |
| Northern Trust Wilshire 5000 | 1.97K | 0.00% | 0.00% | Jun 2024 |
| NT Ext Equity Mkt Idx Fd - NL | 1.80K | 0.04% | 0.00% | Sep 2024 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1.45K | 0.03% | +0.28% | Sep 2024 |
| Vanguard U.S. Eq Idx £ Acc | 1.03K | 0.02% | 0.00% | Sep 2024 |
| Extended Equity Market Fund M | 659.00 | 0.01% | -0.30% | Sep 2024 |
| NT US Market Cap Idx Fd - L | 417.00 | 0.00% | -83.47% | Dec 2023 |
Top institutions holding ORGS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BNP Paribas Arbitrage, SA | 0.00 | 0.00% | -100.00% | Dec 2024 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Vanguard Group Inc | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Dec 2024 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Northern Trust Investments N A | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Mar 2025 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Bank of America Corp | 0.00 | 0.00% | -100.00% | Dec 2024 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Dec 2024 |
Orgenesis Inc company profile
- Company name
- Orgenesis Inc
- Ticker
- ORGS.US
- Exchange
- USA Stocks
- Listed since
- Mar 12, 2012
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 77
- Fiscal year end
- December
- Address
- 20271 Goldenrod Lane, Germantown, MD, United States, 20876
- Phone
- 480 659 6404
- Website
- orgenesis.com
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Orgenesis Inc management
4- Ms. Vered Caplan M.Sc.Chairperson of the Board, CEO & President · born 1969
- Prof. Sarah Ferber Ph.D.Founder & Chief Scientific Officer · born 1954
- Mr. Douglas KarrikerCFO, Treasurer & Secretary · born 1975
- Dr. Shimon Hassin Ph.D.Chief Technology Officer